MELBOURNE, Australia and INDIANAPOLIS, March  02, 2026  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, &#34;Telix&#34;) invites investors to join a webinar with key opinion leaders to discuss a

Investor Education Webinar

Telix to Host Webinar on Advances in Prostate Cancer Imaging

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, &amp;#34;Telix&amp;#34;) invites investors to join a webinar with key opinion leaders to discuss a
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Telix Pharmaceuticals is hosting a webinar featuring key opinion leaders discussing innovations in PSMA-PET/CT imaging for prostate cancer. This event, occurring on March 4, 2026, highlights Telix&#039;s commitment to advancing its diagnostic capabilities, potentially boosting investor confidence and interest in its oncology products.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Telix Pharmaceuticals will host a webinar on PSMA-PET/CT imaging innovations.</li><li>Key opinion leaders will discuss prostate cancer treatment advancements.</li><li>The webinar features notable medical professionals and Telix executives.</li><li>Event scheduled for March 4, 2026, at 5:30 p.m. EST.</li><li>Telix focuses on therapeutic and diagnostic radiopharmaceutical development.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>UroPartners (N/A): Expertise in clinical navigation could complement Telix&#039;s imaging innovations.</li><li>Ascension Saint Joseph Hospital (N/A): Involvement of its chief of urology highlights clinical significance of Telix&#039;s innovations.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This article fits within the &#039;Corporate Developments&#039; category due to Telix&#039;s strategic engagement with key opinion leaders, which can potentially enhance its market presence and product awareness.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Increased visibility from the upcoming webinar may enhance investor confidence.</li><li>Expert insights could lead to positive sentiment around Telix&#039;s oncology pipeline.</li><li>Growing demand for innovative imaging solutions can benefit TLX&#039;s market position.</li><li>Future collaborations or partnerships may arise from the discussed innovations.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Telix is focused on radiopharmaceutical development for oncology.</li><li>The webinar is set for March 4, 2026.</li><li>Key speakers include established medical professionals and Telix executives.</li><li>Telix operates in multiple international markets including the US and Europe.</li><li>The company is publicly traded on ASX and NASDAQ.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Consider accumulating TLX shares ahead of the webinar for potential short-term gains.
 </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link>MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TLX">TLX</a>, "Telix") invites investors to join a webinar with key opinion leaders to discuss a physician's perspective on innovations in PSMA-PET/CT imaging for prostate cancer. Speakers: <ul type="disc"><li style="text-align:justify;">Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Executive Chairman and Chief Medical Officer at the Melbourne Theranostic Innovation Centre (MTIC);</li><li style="text-align:justify;">Paul Yonover, MD, FACS, Chief Data Officer and Director of Clinical Navigation at UroPartners, a division of The Specialty Alliance; Chief of Urology at Ascension Saint Joseph Hospital, Chicago; and</li><li style="text-align:justify;">Darren Patti, PharmD, Telix Group Chief Operating Officer. </li></ul> The webinar will be moderated by David N. Cade, MD, Telix Group Chief Medical Officer. The webinar will be held on: EST: Wednesday March 4, 2026, 5:30 p.m. AEDT: Thursday March 5, 2026, 9:30 a.m. The event will run for approximately one hour. Participants can register for the webcast at the following link: <a href="https://www.globenewswire.com/Tracker?data=5rwQqkGCyWO5J5D36MUGT2TN-vfoqvt5LXTBWwhOF3_FSrCb036tode8txRKTFSuWPHNLm3QQOC_O38PU50dYbjgnl5KVB82Fdp8RLIAkxqPDs62rN0JTcJbrYLOzsnhGS8k0HSbeOPKyYM7KPpo-b4ERWUSdJbh_cY_tKA_5aU=" rel="nofollow" target="_blank">https://edge.media-server.com/mmc/p/n87mam6r</a> About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TLX">TLX</a>). Visit <a href="https://www.globenewswire.com/Tracker?data=tCdUZosMZebUZiFdpf9AQDPRRpzv7ZJwaAwmWRYHZ383ubh3v0idioDT8wa4xdUoyNYNBN822bcBpZ4gs4JUN540E3TiKaXExlMUHb0NBX4=" rel="nofollow" target="_blank">www.telixpharma.com</a> for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on <a href="https://www.globenewswire.com/Tracker?data=5fmKaBzzg-ZKrXEZxsHpf3jZAdH-2bPvSr0gYcUpwjuNcUTfl-z40-KlXc4XVdeEiyD7UDs50TKg___T8M0FKPkw6qsUq7oApDbT-dBYbRk=" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=H0gSgzw-p2jWlgCMtvjeIrbnt1A85eVYQ1T2yGuoZh5coCzLre-UUl7BnexTWJjzCjT1dgssFWIt6_cMFBQ85g==" rel="nofollow" target="_blank">X</a> and <a href="https://www.globenewswire.com/Tracker?data=H7QbqB0yBYqRpb7-ouv1qBfbpKpT6coYo-hfHX_LIb13i4rOHMLsfxog5L2mKj0EMWgNeFWUOxvdA-Jwzt2l5C_dkMGvwZ9N8zA9fDLhueQ=" rel="nofollow" target="_blank">Facebook</a>. <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:34%; width:34%; min-width:34%;;text-align: left ; vertical-align: middle; vertical-align: top ; ">Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications <a href="mailto:kyahn.williamson@telixpharma.com" rel="nofollow" target="_blank">kyahn.williamson@telixpharma.com</a></td><td style="max-width:33%; width:33%; min-width:33%;;text-align: left ; vertical-align: middle; vertical-align: top ; ">Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations <a href="mailto:charlene.jaw@telixpharma.com" rel="nofollow" target="_blank">charlene.jaw@telixpharma.com</a></td><td style="max-width:33%; width:33%; min-width:33%;;vertical-align: top ; ">Telix Investor Relations (U.S.)  Ms. Annie Kasparian  Director Investor Relations and Corporate Communications  <a href="mailto:annie.kasparian@telixpharma.com" rel="nofollow" target="_blank">annie.kasparian@telixpharma.com</a></td></tr></table> Legal Notices Cautionary Statement Regarding Forward-Looking Statements.  You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the &#xAE; or &#x2122; symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. &#xA9;2026 Telix Pharmaceuticals Limited. All rights reserved. <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2MzU3NCM3NDYxNDAwIzIwODMyNDI="></img> <img alt="" src="https://ml.globenewswire.com/media/YzIxZWNlM2ItMzExYS00ZjczLThkN2QtYjA0MWZmZWU2MjBlLTEwOTQ4MTMtMjAyNi0wMy0wMS1lbg==/tiny/Telix-Pharmaceuticals-Limited.png" referrerpolicy="no-referrer-when-downgrade"></img><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/77ceffdf-31cc-415f-9747-efee950af329"><img src="https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png" border="0" width="150" height="62" alt="Primary Logo"></img></a>

Telix Pharmaceuticals is hosting a webinar featuring key opinion leaders discussing innovations in PSMA-PET/CT imaging for prostate cancer. This event, occurring on March 4, 2026, highlights Telix's commitment to advancing its diagnostic capabilities, potentially boosting investor confidence and interest in its oncology products.

Investor Education Webinar

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News